About three weeks ago, the U.S. Food and Drug Administration approved the MiniMed 670g, Medtronic’s hybrid closed loop system, for people with diabetes over the age of 14.
This news has generated a lot of excitement, and also a lot of questions. I was fortunate enough to connect a little over a week ago with Karrie Hawbaker and Michael Hill of Medtronic Diabetes (which is why then I was saying the approval was two weeks ago), who went on the record about how the 670g works, the new CGM sensor associated with the 670g, and the upgrade pathway for existing Medtronic customers. Which is still a little murky, but they recognize that every customer is different, and they’re willing to talk to you about it. There’s also a little at the end about how Medtronic is leveraging IBM’s Watson supercomputer to crunch data.
Here then, is everything you want to know about the 670g. Thanks Karrie and Mike!
Reference Material – Click below for more information on this topic
Karrie Hawbaker is Senior Manager of Social Media for Medtronic Diabetes, and Michael Hill is Vice President of Global Marketing in the Intensive Insulin Management business unit at Medtronic:
medtronicdiabetes.com
If you’re an existing Medtronic pumper, and you’re interested in upgrading to the 670g in the spring, here is all the information on the Priority Access Program:
medtronicdiabetes.com/products/priority-access
Diabetes Blog - Happy-Medium.net 
Comments
That’s a very insightful interview. I read about Type 1 diabetes patient who was in the clinical studies for 670G and his review is quite fantastic. I really like how you only have to worry about the bolus because automation keeps the basal injections in check.
Can’t wait for the launch.
Best,
Steve
LikeLiked by 1 person